Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents

详细信息    查看全文

• 作者：Takahide Arai (1) tarai@cpnet.med.keio.ac.jp
  Akio Kawamura (1)
  Yumiko Matsubara (2)
  Kenji Yokoyama (2)
  Yasuo Ikeda (2)
  Keiichi Fukuda (1)
  Mitsuru Murata (2)
• 关键词：Platelets &#8211 ; Dual ; antiplatelet therapy &#8211 ; PFA ; 100 analyzer &#8211 ; Light transmittance aggregometry
• 刊名：Heart and Vessels
• 出版年：2012
• 出版时间：September 2012
• 年：2012
• 卷：27
• 期：5
• 页码：480-485
• 全文大小：185.5 KB
• 参考文献：1. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB (2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356(10):998–1008
  2. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schomig A (2007) Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356(10):1030–1039
  3. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW (2004) Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364(9444):1519–1521
  4. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369(9562):667–678
  5. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S, Windecker S (2008) Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 52(14):1134–1140
  6. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, Nishikawa H, Hiasa Y, Muramatsu T, Meguro T, Inoue N, Honda H, Hayashi Y, Miyazaki S, Oshima S, Honda T, Shiode N, Namura M, Sone T, Nobuyoshi M, Kita T, Mitsudo K (2009) Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 119(7):987–995
  7. Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, Buonamici P, Gensini GF, Vergara R, Abbate R, Antoniucci D (2008) Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 52(9):734–739
  8. Fuchs I, Frossard M, Spiel A, Riedmuller E, Laggner AN, Jilma B (2006) Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 4(12):2547–2552
  9. Favaloro EJ (2002) Clinical application of the PFA-100. Curr Opin Hematol 9(5):407–415
  10. Matsubara Y, Murata M, Watanabe G, Ikeda Y (2008) Enhancing effect of the (145)Met-allele of GPIb alpha on platelet sensitivity to aspirin under high-shear conditions. Thromb Res 123(2):331–335
  11. Siller-Matula JM, Haberl K, Prillinger K, Panzer S, Lang I, Jilma B (2009) The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. Thromb Res 123(6):874–880
  12. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL, Alessi MC (2006) High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4(3):542–549
  13. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA (2007) Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 49(6):657–666
  14. Crescente M, Di Castelnuovo A, Iacoviello L, de Gaetano G, Cerletti C (2008) PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients. Thromb Haemost 99(6):1129–1131
  15. Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A (2003) Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 34(4):849–854
  16. Muller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schomig A, Gawaz M (2001) Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85(1):92–93
  17. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A (2005) Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112(19):2946–2950
  18. Fukushima K, Kobayashi Y, Kitahara H, Iwata Y, Kuroda N, Ooyama M, Nomura F, Komuro I (2010) Effect of 450-mg loading dose of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement. Heart Vessels 25(3):182–186
  19. Fukushima K, Kobayashi Y, Kitahara H, Iwata Y, Kuroda N, Ooyama M, Kuwabara Y, Nomura F, Komuro I (2010) Antiplatelet effect of 50-mg maintenance dose of clopidogrel compared to 200 mg ticlopidine: a preliminary study. Heart Vessels 25(1):41–44
  20. Awidi A, Saleh A, Dweik M, Kailani B, Abu-Fara M, Nabulsi R, Bener A (2010) Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study. Heart Vessels. [Epub ahead of print]
  21. Tanrikulu AM, Ozben B, Koc M, Papila-Topal N, Ozben T, Caymaz (2011) O Aspirin resistance in patients with chronic renal failure. J Nephrol. [Epub ahead of print]
  22. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J (2004) Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65(3):1009–1016
  23. Park SH, Kim W, Park CS, Kang WY, Hwang SH (2009) A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 104(9):1292–1295
  24. Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabate M, Ferreiro JL, Ueno M, Jimenez-Quevedo P, Alfonso F, Bass TA, Macaya C, Fernandez-Ortiz A (2010) A impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 55(11):1139–1146
  25. Boccardo P, Remuzzi G, Galbusera M (2004) Platelet dysfunction in renal failure. Semin Thromb Hemost 30(5):579–589
  26. Escolar G, Diaz-Ricart M, Cases A (2005) Uremic platelet dysfunction: past and present. Curr Hematol Rep 4(5):359–367
  27. Kaw D, Malhotra D (2006) Platelet dysfunction and end-stage renal disease. Semin Dial 19(4):317–322
• 作者单位：1. Department of Internal Medicine, Division of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582 Japan2. Department of Internal Medicine, Division of Hematology, Keio University School of Medicine, Tokyo, Japan
• ISSN：1615-2573

文摘

We investigated the effect of chronic kidney disease (CKD) on platelet function in patients receiving dual-antiplatelet therapy after drug-eluting stent (DES) implantation. We examined 19 patients with CKD and 18 patients without CKD who underwent percutaneous coronary intervention (PCI) with DES. All of the patients had been on chronic aspirin treatment. Blood samples were obtained 20–24 h after a loading dose (300 mg) of clopidogrel. Platelet function was evaluated by measuring the closure time (CT) of a collagen/epinephrine (CEPI) or collagen/adenosine diphosphate (CADP) cartridge in the PFA-100 system. Maximum aggregation of agonist (epinephrine, ADP, collagen, or ristocetin)-induced platelet aggregation was also examined by light transmittance aggregometry. The frequency of the poor responders among CKD (n = 9, 47.4%) patients was significantly higher than that among non-CKD patients (n = 2, 11.1%, P = 0.016) as assessed using a CEPI-CT cartridge. Multiple logistic regression analysis revealed that CKD (odds ratio 7.39, 95% confidence interval 1.38–62.09, P = 0.0183] was the only independent determinant of the poor responders. There were no significant differences between the two groups in the value of CADP-CT or in maximum aggregation of epinephrine-, ADP-, collagen-, and ristocetin-induced platelet aggregation. Compared with non-CKD patients, CKD patients had lower response to aspirin therapy as assessed by the PFA-100 system with a CEPI cartridge. On the other hand, the platelet response to dual-antiplatelet therapy was not different between CKD and non-CKD patients.